SkyePharma AG
Quick facts
Phase 3 pipeline
- Flovent Fluticasone HFA · Respiratory / Pulmonology
Fluticasone propionate is an inhaled corticosteroid that reduces airway inflammation by binding to glucocorticoid receptors and suppressing inflammatory mediator production. - Fluticasone propionate 100 · Respiratory / Pulmonology
Fluticasone propionate is a corticosteroid that suppresses inflammatory and immune responses by binding to glucocorticoid receptors in target tissues. - Fluticasone propionate 250 · Respiratory / Pulmonology
Fluticasone propionate is a corticosteroid that suppresses inflammatory and immune responses by binding to glucocorticoid receptors in target tissues. - Fluticasone propionate/formoterol fumarate · Respiratory/Pulmonology
Fluticasone propionate/formoterol fumarate combines a corticosteroid that reduces airway inflammation with a long-acting beta-2 agonist that relaxes airway smooth muscle. - FlutiForm 250/10 · Respiratory/Pulmonology
FlutiForm combines fluticasone propionate (an inhaled corticosteroid) with formoterol (a long-acting beta-2 agonist) to reduce airway inflammation and improve bronchial smooth muscle relaxation. - Formoterol fumarate 10 · Respiratory
Formoterol fumarate is a long-acting beta-2 adrenergic agonist that binds to beta-2 receptors on airway smooth muscle to cause bronchodilation and improve airflow. - SKP-Fluticasone · Respiratory / Pulmonology
SKP-Fluticasone is a corticosteroid that reduces inflammation by binding to glucocorticoid receptors and suppressing immune and inflammatory responses. - SKP FlutiForm HFA pMDI · Respiratory/Pulmonology
SKP FlutiForm HFA is a combination inhaled corticosteroid (fluticasone propionate) and long-acting beta-2 agonist (formoterol) delivered via pressurized metered-dose inhaler for maintenance treatment of asthma.
Phase 1 pipeline
Competitive intelligence
For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors: